Overview
Founded in Mol in 2022 as a joint venture between SCK CEN (Belgian Nuclear Research Centre) and IBA (Ion Beam Applications), PanTera is developing large-scale production capacity for actinium-225, a radioactive isotope used in targeted alpha therapy for cancer treatment.
Actinium-225 is in extremely short global supply relative to demand from pharmaceutical companies developing next-generation radiopharmaceutical drugs. PanTera's facility in Mol, which already hosts one of Europe's major nuclear research sites, is positioned to become a key supplier to this growing therapeutic category.
The company raised EUR 93M led by EQT Life Sciences as part of a EUR 134M total raise, the largest single life sciences funding round in Belgian history. The capital supports production scale-up and regulatory validation of supply chains for pharmaceutical-grade actinium-225.
Funding & milestones
1 events found for PanTera · 2024
GrowthVenture / equityDetailsEUR 134M
Reported amount EUR 134,000,000
Source not attached to this recordDeal record
Recorded history so far. Original currencies are preserved; amounts in different currencies are not added together. Debt, grants, acquisitions and listings are separate event types. Undated events appear last.
Profile narrative
- Growth round, EUR 93M (EUR 134M total), 2024: EQT Life Sciences (lead)
Key people
In the news
Related profiles
Something wrong or missing? Send an update. Fixed within 24 hours.